Discover
GNLX
Genelux Corporation
2.90
2 x 2.17
2 x 3.69
bid
ask
-
0.11
3.65%
2 @ 04:00 PM
2.90 +0.00 (0.00%)
| Ytd | -33.49% | |
| 1y | 2.47% |
2.87
day range
3.05
2.29
52 week range
8.54
| Open | 3.03 | Prev Close | 3.01 | Low | 2.87 | High | 3.05 | Mkt Cap | 130.04M |
| Vol | 161.97K | Avg Vol | 190.03K | EPS | -0.85 | P/E | N/A | Forward P/E | -2.45 |
| Beta | N/A | Short Ratio | 8.90 | Inst. Own | 15.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 2.88 | 200-d Avg | 3.70 | 1yr Est | 18.40 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.19 | -0.19 | N/A | N/A |
| 2024-08-14 | 2024-06 | -0.19 | N/A | N/A | N/A |
| 2024-08-14 | 2024-06 | -0.19 | -0.22 | -0.03 | -15.79% |
| 2024-03-29 | 2023-12 | -0.21 | N/A | N/A | N/A |
| 2024-03-29 | 2023-12 | -0.21 | -0.25 | -0.04 | -19.05% |
| 2023-11-14 | 2023-09 | -0.12 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-29 | Guggenheim | Upgrade | Buy | |
| 2024-08-27 | Roth MKM | Upgrade | Buy | |
| 2024-08-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-03 | Benchmark | Upgrade | Speculative Buy | Speculative Buy |
| 2024-05-31 | Benchmark | Upgrade | Speculative Buy | Speculative Buy |
Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-12-17 | CAPPELLO JOSEPH | Officer | 43.65K | Stock Award(Grant) |
| 2024-07-31 | MIRABELLI MARY | Director | 52.00K | Stock Award(Grant) |
| 2024-12-17 | RYDER SEAN | General Counsel | 41.39K | Stock Award(Grant) |
| 2024-12-17 | SMALLING RALPH | Officer | 31.85K | Stock Award(Grant) |
| 2024-07-31 | SMITHER JOHN W | Director | 52.71K | Stock Award(Grant) |
| 2024-09-12 | SZALAY ALADAR | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Woodward Diversified Capital, LLC | 1.34M | 3.09M | 3.89% |
| 2024-09-29 | Vanguard Group Inc | 984.85K | 2.27M | 2.85% |
| 2024-09-29 | Millennium Management Llc | 364.93K | 839.34K | 1.06% |
| 2024-09-29 | Geode Capital Management, LLC | 316.16K | 727.17K | 0.92% |
| 2024-09-29 | Blackrock Inc. | 310.29K | 713.66K | 0.90% |
| 2024-09-29 | Bank of America Corporation | 216.78K | 498.60K | 0.63% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 679.80K | 1.56M | 1.97% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 284.12K | 653.47K | 0.82% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 158.40K | 364.32K | 0.46% |
| 2024-08-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 90.65K | 208.50K | 0.26% |
| 2024-10-30 | iShares Micro Cap ETF | 61.76K | 142.05K | 0.18% |
| 2024-10-30 | Fidelity Total Market Index Fund | 51.78K | 119.09K | 0.15% |